Kzra D 40 Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone is a dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. Kzra D 40 Capsule SR is indicated for patients suffering from acid reflux accompanied by delayed gastric emptying or motility disorders. It should be used under medical supervision, with caution advised in patients with hepatic impairment or those on medications that may interact with either component. Common adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. This combination therapy offers a synergistic approach to managing complex upper gastrointestinal symptoms by addressing both acid suppression and motility enhancement.